ARS Pharmaceuticals (SPRY) Competitors $15.26 +0.54 (+3.67%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SPRY vs. CYTK, BPMC, KRYS, RNA, BHVN, CRNX, BBIO, ACLX, IBRX, and OGNShould you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Cytokinetics (CYTK), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), Avidity Biosciences (RNA), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), BridgeBio Pharma (BBIO), Arcellx (ACLX), ImmunityBio (IBRX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. ARS Pharmaceuticals vs. Cytokinetics Blueprint Medicines Krystal Biotech Avidity Biosciences Biohaven Crinetics Pharmaceuticals BridgeBio Pharma Arcellx ImmunityBio Organon & Co. Cytokinetics (NASDAQ:CYTK) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability. Does the MarketBeat Community favor CYTK or SPRY? Cytokinetics received 779 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 79.56% of users gave Cytokinetics an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes79879.56% Underperform Votes20520.44% ARS PharmaceuticalsOutperform Votes1982.61% Underperform Votes417.39% Which has more risk and volatility, CYTK or SPRY? Cytokinetics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Which has higher valuation and earnings, CYTK or SPRY? ARS Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$7.53M809.71-$526.24M-$5.37-9.65ARS Pharmaceuticals$30K49,310.15-$54.37M-$0.47-32.47 Do analysts recommend CYTK or SPRY? Cytokinetics currently has a consensus target price of $83.93, indicating a potential upside of 61.96%. ARS Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 57.27%. Given Cytokinetics' higher possible upside, analysts clearly believe Cytokinetics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.73ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Do institutionals & insiders have more ownership in CYTK or SPRY? 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.4% of Cytokinetics shares are held by company insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CYTK or SPRY more profitable? ARS Pharmaceuticals has a net margin of 0.00% compared to Cytokinetics' net margin of -17,398.82%. Cytokinetics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,398.82% N/A -55.97% ARS Pharmaceuticals N/A -19.77%-19.26% Does the media favor CYTK or SPRY? In the previous week, Cytokinetics had 4 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Cytokinetics and 2 mentions for ARS Pharmaceuticals. Cytokinetics' average media sentiment score of 0.42 beat ARS Pharmaceuticals' score of 0.36 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryARS Pharmaceuticals beats Cytokinetics on 11 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRY vs. The Competition Export to ExcelMetricARS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.48B$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-32.479.84114.8315.12Price / Sales49,310.15401.431,497.30100.87Price / CashN/A47.3939.6834.09Price / Book6.365.324.665.02Net Income-$54.37M$153.56M$119.06M$225.46M7 Day Performance3.32%0.13%0.80%0.37%1 Month Performance5.61%15.23%5.65%3.57%1 Year Performance318.08%41.14%36.75%29.43% ARS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRYARS Pharmaceuticals2.8441 of 5 stars$15.26+3.7%$24.00+57.3%+328.7%$1.48B$30,000.00-32.4790CYTKCytokinetics4.2687 of 5 stars$52.54+2.4%$83.93+59.7%+47.6%$5.51B$3.13M-9.78250Upcoming EarningsInsider SellingShort Interest ↓BPMCBlueprint Medicines2.218 of 5 stars$81.86-0.7%$118.22+44.4%+51.4%$5.13B$362.80M-23.94640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.639 of 5 stars$177.75+1.3%$196.75+10.7%+47.8%$5.11B$50.70M48.70229Upcoming EarningsRNAAvidity Biosciences2.2552 of 5 stars$45.63+1.2%$62.67+37.3%+717.8%$5.01B$9.56M-15.52190Analyst ForecastBHVNBiohaven2.6476 of 5 stars$53.74+1.7%$61.92+15.2%+72.5%$4.74B$462.51M-5.87239CRNXCrinetics Pharmaceuticals3.052 of 5 stars$58.19+0.4%$68.55+17.8%+91.8%$4.59B$1.39M-15.39210Negative NewsBBIOBridgeBio Pharma4.5444 of 5 stars$24.52+2.9%$47.50+93.7%-4.4%$4.59B$219.12M-9.32400Upcoming EarningsACLXArcellx1.4875 of 5 stars$84.43+0.1%$89.75+6.3%+150.6%$4.52B$144.75M-81.18130Analyst ForecastShort Interest ↑News CoverageIBRXImmunityBio0.8202 of 5 stars$6.50+22.2%$4.75-26.9%+62.5%$4.50B$1.31M-6.70590Gap UpHigh Trading VolumeOGNOrganon & Co.4.7 of 5 stars$17.37+1.2%$21.33+22.8%+23.2%$4.47B$6.35B4.4710,000Dividend AnnouncementNews Coverage Related Companies and Tools Related Companies CYTK Competitors BPMC Competitors KRYS Competitors RNA Competitors BHVN Competitors CRNX Competitors BBIO Competitors ACLX Competitors IBRX Competitors OGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRY) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
